Rezolute Inc
Change company Symbol lookup
Select an option...
RZLT Rezolute Inc
ALT Altimmune Inc
BNKU MicroSectors? U.S. Big Banks Index 3X Leveraged ETNs
SGFY Signify Health Inc
FRC First Republic Bank
BACK IMAC Holdings Inc
LYLT Loyalty Ventures Inc
BOXD Boxed Inc
ALLR Allarity Therapeutics Inc
SIVB SVB Financial Group

Health Care : Biotechnology | Small Cap Value
Company profile

Rezolute, Inc. (Rezolute) is a clinical-stage biopharmaceutical company, which is engaged in developing therapies for metabolic diseases related to chronic glucose imbalance. The Company’s lead clinical asset, RZ358, is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. The antibody modifies insulin’s binding and signaling to maintain glucose levels in a normal range, which counteracts the effects of elevated insulin in the body. It is a potential treatment for congenital hyperinsulinism (HI), which is an ultra-rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas in Phase II. The Company is also developing RZ402, an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME) in Phase I.

Day's Change
0.00 (0.00%)
B/A Size
Day's High
Day's Low

Today's volume of 100 shares is on pace to be much lighter than RZLT's 10-day average volume of 34,584 shares.


Burlington Stories earnings fall short of estimates and CEO says 'not happy' with its performance

7:00 am ET November 22, 2022 (MarketWatch)

Burlington Stores Inc. stock slid 1.7% in premarket trade Tuesday before reversing those losses to trade flat, after the discount clothing retailer posted weaker-than-expected third-quarter earnings and Chief Executive Michael O'Sullivan said it was "not happy" with its performance. The company had net income of $17 million, or 26 cents a share, for the quarter, up from $14 million, or 20 cents a share, in the year-earlier period. Adjusted per-share earnings came to 43 cents, below the 52 cent FactSet consensus. Sales fell 11% to $2.036 billion, also below the $2.055 billion FactSet consensus. Same-store sales fell 17%, while FactSet was forecasting a 16.6% decline. "As we said on our August earnings call, as an off-price retailer we should be able to perform better in this environment despite the significant macro headwinds," said O'Sullivan. "Recent results from other off-price retailers reinforce this view." The customers' frame of reference for value shifted significantly in 2022, he added, and Burlington did not react aggressively enough. But the company is upbeat for 2023 and believes it can set up well for off-price. "We also recognize that we will be lapping our own execution mistakes and under-performance from 2022. Based on these factors we believe that we can start to drive significant sales, margin, and earnings recovery next year," he said. The company is now expecting full-year same-store sales to fall 15% to 14%, compared with a FactSet consensus for a decline of 14.6%. It expects adjusted EPS of $3.77 to $4.07, compared with a FactSet consensus of $4.00. Shares have fallen 46% in the year to date, while the S&P 500 has fallen 17%.

-Ciara Linnane


(END) Dow Jones Newswires

November 22, 2022 07:00 ET (12:00 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.